Indications
Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.
Composition
- Active substance
- osilodrostat phosphate
- International name (INN)
- osilodrostat
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Isturisa
- Active substance
- osilodrostat phosphate
- ATC code
- H02CA02
- Therapeutic area
- Cushing Syndrome
- Marketing authorisation holder
- Recordati Rare Diseases
- Status
- Authorised